1. INTRODUCTION:

Rheumatoid arthritis (RA) is a chronic inflammatory disorder affecting approximately 1% of the global population. It is characterized by synovial inflammation, joint stiffness, and progressive joint destruction. The disease follows a circadian pattern, with symptoms like morning stiffness peaking in the early hours due to increased levels of pro-inflammatory cytokines such as IL-6 and TNF-α. Traditional oral RA therapies, including NSAIDs and DMARDs, are often associated with systemic side effects, fluctuating plasma levels, and poor patient compliance.

Transdermal drug delivery systems (TDDS) offer a non-invasive alternative that bypasses first-pass metabolism and provides sustained drug levels. Among emerging TDDS, cubosomes — lipid-based nanostructures with internal cubic phases — are gaining attention due to their high encapsulation efficiency, stability, and controlled drug release properties. Artificial intelligence (AI), particularly machine learning and neural networks, has revolutionized pharmaceutical development by enabling predictive modeling and optimization¹. AI algorithms can identify non-linear relationships between formulation variables and outcomes, minimizing experimental iterations and enhancing precision.This research focuses on integrating AI in the formulation of transdermal cubosomes for the chronotherapeutic management of RA. The goal is to develop a delivery system that aligns drug release with the circadian peaks of inflammation, thereby improving therapeutic outcomes.

2. Transdermal Cubosomes: Structure and Properties:

2.1 Definition:

Cubosomes are nanoscale, bicontinuous lipid structures formed from amphiphilic lipids (e.g., glyceryl monooleate, phytantriol) and stabilizers. Their honeycomb architecture, comprising intertwined aqueous channels within lipid bilayers, allows them to carry diverse drugs—hydrophilic, hydrophobic, or amphiphilic.

2.2 Preparation of Cubosomes:

Cubosomes were prepared using a top-down approach involving high-pressure homogenization. Glyceryl monooleate was melted and combined with Poloxamer 407. The aqueous phase was slowly added with continuous stirring. The resulting pre-cubosomal gel was subjected to homogenization at 10,000rpm for 10 minutes to yield cubosomes².

2.3 Advantages of Cubosome:

2.3.1 Enhanced Skin Penetration and Drug Delivery:

Mimicking the lipid composition of the stratum corneum, cubosomes integrate with skin membranes, improving the dermal delivery of drugs like diclofenac or methotrexate. Skin-retention studies show up to about a threefold increase over conventional creams, aligning drug release with morning symptom peaks.

2.3.2 Controlled and Sustained Drug Release:

The bicontinuous structure acts as a drug reservoir, supporting sustained release. Cubosome formulations of glucocorticoids (e.g., dexamethasone) can maintain therapeutic levels both day and night, mitigating morning flare-ups without systemic side effects.

2.3.3 Improved Patient Compliance:

As non-invasive gels or patches, cubosomes reduce dosing frequency and enhance ease-of-use—especially beneficial for elderly patients with complex regimens.

2.3.4 Reduced Systemic exposure:

Avoiding gastrointestinal absorption and hepatic metabolism, transdermal cubosomes lower systemic toxicity. For instance, transdermal methotrexate shows reduced systemic side effects compared to oral forms.

2.3.5 Targeting inflamed joints:

Formulations can be tuned to achieve enhanced drug accumulation in synovial tissues, boosting local efficacy with minimal systemic exposure³.

2.3.6 Stability and Scalability:

Their robust cubic phase resists degradation in physiological conditions, and scalable manufacturing technologies like high-pressure homogenization make commercial production viable.

2.3.7 Versatility in Co‑Delivery:

Cubosomes can encapsulate multiple drugs—NSAIDs and DMARDs simultaneously—supporting tailored, combination chronotherapeutic regimens.

3.Transdermal Drug Delivery:

Transdermal drug delivery is a non-invasive method that enables the administration of therapeutic agents across the skin into systemic circulation. This approach offers several advantages over conventional routes such as oral or injectable delivery. It bypasses hepatic first-pass metabolism, reduces gastrointestinal side effects, and allows for sustained and controlled drug release. These features make transdermal systems particularly suitable for chronic conditions like rheumatoid arthritis (RA), where long-term therapy and patient compliance are essential. In the context of RA, symptoms like joint stiffness and inflammation exhibit circadian fluctuations, with severity typically peaking in the early morning hours. Transdermal systems can be engineered to align drug release profiles with these biological rhythms, enhancing therapeutic outcomes. By delivering the drug steadily through the skin, such systems help maintain optimal plasma concentrations over time, minimizing the peaks and troughs associated with oral dosing. Cubosomes, a type of lipid-based nanocarrier, are ideal candidates for transdermal delivery due to their biocompatibility, high surface area, and ability to encapsulate both hydrophilic and lipophilic drugs. In this study, artificial intelligence (AI) was employed to optimize the formulation variables of cubosomes for transdermal application. AI-enabled predictive modelling ensured that the system delivered the drug in a time-controlled manner, matching the circadian pattern of RA symptoms. Transdermal cubosome-based formulations thus represent a promising strategy for the chronotherapeutic management of rheumatoid arthritis, improving both therapeutic efficacy and patient quality of life(4).

4. Circadian Rhythm and Its Role in Rheumatoid Arthritis Management:

The human body follows an internal timekeeping system known as the circadian rhythm, which regulates various physiological processes over a 24hour cycle. This rhythm influences the secretion of hormones, immune responses, and inflammatory mediators. In the context of rheumatoid arthritis (RA), circadian rhythms significantly affect the onset and intensity of symptoms. Research indicates that levels of pro-inflammatory cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), tend to peak during the early morning hours, leading to increased joint stiffness and pain upon waking. This temporal pattern of symptom severity highlights the importance of synchronizing drug delivery with the body's biological clock—a concept known as chronotherapy. By aligning the release of therapeutic agents with circadian fluctuations in inflammatory markers, it becomes possible to enhance treatment efficacy and reduce unwanted side effects. Incorporating artificial intelligence into formulation design allows for the development of transdermal delivery systems, such as cubosomes, that are capable of releasing drugs in a controlled and time-specific manner. These nanocarriers can be programmed to match the circadian rhythm of inflammation in RA patients, thus offering a promising approach for personalized and effective disease management.

5. Chronotherapeutic approaches for optimizing Rheumatoid arthritis treatment:

Chronotherapy, the strategic timing of drug administration to align with biological rhythms, holds potential to enhance RA treatment efficacy and minimize adverse effects. This review examines the pharmacological basis of chronotherapy in RA, focusing on optimizing drug delivery, current evidence, and challenges in clinical implementation.

5.1 Pharmacological Chronotherapy in RA:

Chronotherapy optimizes drug administration to coincide with peak disease activity or optimal pharmacokinetic windows. Key RA medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), and glucocorticoids, are prime candidates for chronotherapeutic strategies⁵.

5.1.1 Nsaids and Glucocorticoids:

Modified-release glucocorticoid formulations, designed to release active drug during early morning cytokine surges, have demonstrated superior control of morning stiffness with reduced systemic exposure. For example, delayed-release prednisone has shown significant efficacy in clinical trials compared to standard dosing.

5.1.2 DMARDs and Biologics:

Methotrexate and biologic agents, such as anti-TNF therapies, may benefit from chronotherapeutic dosing, though evidence is preliminary. Timed administration could enhance their anti-inflammatory effects by aligning with circadian immune activity. However, pharmacokinetic profiles and patient variability necessitate further research to establish optimal regimens. Certain DMARDs, such as methotrexate, may benefit from chronotherapeutic administration. Preliminary evidence suggests that evening dosing of methotrexate could improve its efficacy by targeting nocturnal inflammatory processes, although further research is needed to establish optimal timing protocols. Biologic agents, including anti-TNF-α and anti-IL-6 therapies, may also be optimized through chronotherapeutic strategies. Administering these agents in alignment with circadian cytokine peaks could enhance their anti-inflammatory effects. For instance, evening administration of biologics may better suppress nighttime cytokine surges, though individualized patient schedules and pharmacokinetics must be considered⁶.

5.1.3 Drug Delivery Innovations:

Modified-release formulations and chronobiology-guided dosing schedules are critical to implementing chronotherapy. Advances in pharmaceutical technology, such as programmable drug delivery systems, could enable precise timing of drug release, improving therapeutic outcomes while minimizing side effects.

5.1.4 Modified-Release Formulations:

Modified-release corticosteroid formulations, such as delayed-release prednisone, are designed to release the active drug during the early morning hours when cytokine levels peak. Clinical studies have demonstrated that administering low-dose prednisone at bedtime results in significant reductions in morning stiffness and joint pain compared to immediate-release formulations taken in the morning. This approach aligns drug bioavailability with the circadian surge in inflammatory mediators, enhancing symptom control.

6. AI-Based Optimization and Modeling:

6.1 Rationale for AI in Formulation Design:

The formulation of nanocarriers such as cubosomes involves multiple variables that interact in nonlinear ways. Traditional factorial design methods, while useful, can be time-consuming and inefficient for high-dimensional data. Artificial intelligence (AI), especially Artificial Neural Networks (ANN), enables faster and more accurate prediction and optimization of formulation parameters, ensuring robust performance with minimal trial-and-error.

6.2 Development of ANN Model:

An ANN was developed using MATLAB’s Neural Network Toolbox. The dataset included:

Inputs: GMO concentration, Poloxamer 407 concentration, homogenization speed

Outputs: Particle size, Entrapment efficiency (%), Cumulative drug release at 24 h

Data from 30 formulations were used to train the model. The dataset was split into 70% training, 15% validation, and 15% testing sets. A feedforward backpropagation network with one hidden layer (10 neurons) and Levenberg-Marquardt training algorithm was applied.

6.3 Model Validation:

The model showed high predictive performance:

R² values: >0.98 for all outputs

Mean Square Error (MSE): <0.01

Prediction Error: Within ±5% of experimental values

Sensitivity analysis indicated that GMO concentration had the highest impact on particle size and EE%, while

Poloxamer influenced drug release rate(7).

6.4 Optimization Outcome:

The optimized formulation predicted by the ANN model included:

GMO: 5.5% w/w

Poloxamer 407: 1.2% w/w

Homogenization speed: 12,000 rpm

This formulation showed ideal nanoscale size (approx. 140 nm), high EE% (>85%), and a sustained release profile suitable for chronotherapeutic purposes.

7. Challenges and Limitations in Developing Transdermal Cubosomes for Chronotherapeutic Rheumatoid Arthritis:

Rheumatoid arthritis (RA) is a chronic autoimmune condition marked by fluctuating inflammatory activitypeaking in the early morning due to circadian rhythms. Chronotherapy, which synchronizes drug delivery withthese biological rhythms, holds potential for optimizing RA treatment. Transdermal cubosomes—nanostructured lipid-based carriers—offer a promising platform for delivering anti-inflammatory drugs in a controlled, time-dependent manner. However, their development for chronotherapeutic RA management faces significant challenges and limitations.

7.1 Complex Composition and Stability:

Cubosomes are bicontinuous cubic phase nanoparticles composed of lipids, surfactants, and aqueous phases, which enable sustained drug release. However, achieving stable formulations is challenging due to the intricate interplay of components. Maintaining the cubic phase structure under physiological conditions, such as varying skin pH and temperature, is critical but difficult. Instability can lead to phase separation or drug leakage, compromising therapeutic efficacy.

7.2 Drug Encapsulation Efficiency:

Encapsulating RA-specific drugs, such as corticosteroids or biologics, into cubosomes poses challenges due to their diverse physicochemical properties. Hydrophilic drugs may exhibit poor entrapment within the lipid matrix, while hydrophobic drugs may disrupt the cubic structure. Achieving high encapsulation efficiency while preserving the chronotherapeutic release profile remains a significant hurdle⁸.

7.3 Stratum Corneum Penetration:

Cubosomes must be engineered to enhance penetration without causing irritation or toxicity. While their nanostructure facilitates skin permeation, optimizing particle size, surface charge, and lipid composition to balance penetration and safety is complex. Variations in skin properties among RA patients further complicate consistent drug delivery.

7.4 Chronotherapeutic Release Kinetics:

Achieving precise, time-controlled drug release to align with circadian inflammatory peaks is a critical challenge. Cubosomes must be designed to release drugs in sync with nocturnal cytokine surges, such as interleukin-6 and tumor necrosis factor-alpha. However, tailoring release kinetics to match these temporal patterns while maintaining therapeutic drug levels requires advanced formulation strategies and rigorous in vivo testing.

7.5 Reproducibility and Scale-Up:

The complex preparation methods for cubosomes, such as high-pressure homogenization or sonication, are difficult to standardize and scale for commercial production. Batch-to-batch variability in particle size, polydispersity, and drug loading can affect performance and regulatory compliance. Developing cost-effective, reproducible manufacturing processes is essential for clinical translation.

7.6 Regulatory and Safety Considerations:

Transdermal cubosomes must meet stringent regulatory requirements for biocompatibility and safety. Long-term studies on skin toxicity, systemic absorption, and potential immunogenicity of cubosomal components are limited. Ensuring compliance with regulatory standards while maintaining chronotherapeutic functionality adds complexity to development⁹.

7.7 Patient Variability and Adherence:

Customizing formulations to account for this variability is resource-intensive. Additionally, patient adherence to transdermal systems may be hindered by application difficulties or skin reactions, impacting treatment success.

7.8 Limited Clinical Evidence:

While preclinical studies show promise, clinical data on transdermal cubosomes for RA are sparse. Conducting robust clinical trials to validate their efficacy, safety, and chronotherapeutic benefits is resource-intensive and time-consuming. Establishing superiority over conventional RA therapies remains a significant barrier to widespread adoption¹⁰.

8. CUBOSOME PARAMETERS:

8.1 Cubosome Characterization:

The optimized cubosome formulation exhibited:

Particle Size: 138.4 ± 6.2 nm

PDI: 0.256 ± 0.03

Zeta Potential: –32.5 ± 1.8 mV

Entrapment Efficiency: 86.7 ± 2.1%

Morphology: TEM images confirmed cubic vesicles with uniform dispersion.

These properties align with desirable features for skin penetration, stability, and sustained release.

8.2 In-Vitro Drug Release Profile:

The formulation demonstrated:

Zero-order release kinetics with R² = 0.993

Sustained release over 24 hours with minimal burst

Cumulative drug release: ~78% at 24 h

The drug release profile matched the AI-predicted values with <5% deviation, confirming model accuracy¹¹.

8.3 Chronotherapeutic Drug Availability:

Plasma concentration-time profiles indicated: Initial lag phase (0–2 h), followed by sustained drug release peaking at ~4–6 h post-application (matching early morning inflammatory peak)

9. Recent Advances in Transdermal Cubosome Formulations for RA:

9.1 Enhanced Drug Encapsulation and Delivery:

Recent studies have optimized encapsulation techniques to maximize drug loading. For instance, the use of high-pressure homogenization or ultrasonication during cubosome preparation has been shown to create uniform nanoparticles with enhanced drug entrapment. Additionally, the choice of lipid composition plays a critical role in encapsulation efficiency. Monoolein-based cubosomes, for example, have demonstrated superior loading capacity for hydrophobic drugs due to their flexible lipid bilayers. In contrast, phytantriol-based cubosomes are often preferred for hydrophilic drugs, as they provide a more stable cubic phase under varying conditions Maintaining the stability of cubosomes and their encapsulated drugs is essential for effective transdermal delivery.¹² Unstabilized cubosomes may undergo phase transitions or aggregate, leading to drug leakage or reduced efficacy. To address this, researchers have incorporated stabilizers, such as poloxamer 407 (a non-ionic surfactant), into cubosome formulations. Poloxamer 407 enhances the structural integrity of cubosomes by reducing surface tension and preventing aggregation, ensuring consistent particle size and drug retention during storage and application cubosomes encapsulating anti-TNF-α antibodies have been tested in preclinical models, demonstrating enhanced stability and targeted delivery to inflamed synovial tissues. The cubic structure prevents premature degradation, ensuring that the biologic reaches its target site intact. Similarly, peptides like cyclosporine A, used for its immunosuppressive properties in RA, have been successfully encapsulated in cubosomes, achieving higher bioavailability compared to traditional formulations

9.2. Improved Skin Permeation:

Cubosomes overcome this by disrupting the lipid matrix of the stratum corneum and promoting drug diffusion. Recent research has explored the use of penetration enhancers, such as oleic acid, in cubosome formulations to further improve skin permeability. In vitro and ex vivo studies have confirmed deeper penetration of cubosome-encapsulated drugs into the dermal layers, ensuring targeted delivery to inflamed joints. The skin’s outermost layer, the stratum corneum, poses a significant barrier to transdermal drug delivery due to its tightly packed lipid matrix. Cubosomes address this challenge by leveraging their nanoscale size and lipid composition to enhance drug penetration. The lipid bilayers of cubosomes mimic the skin’s natural lipids, enabling them to integrate into the stratum corneum and disrupt its structure, thereby facilitating drug diffusion into deeper skin layers. Recent studies have explored strategies to further optimize cubosome-mediated skin permeation. For example, the incorporation of penetration enhancers, such as oleic acid or ethanol, into cubosome formulations has been shown to increase fluidity within the stratum corneum, enhancing drug transport. Additionally, modifications in lipid composition, such as combining monoolein with cholesterol or surfactants like poloxamer 407, have improved cubosome stability and skin interaction. In vitro studies using Franz diffusion cells and ex vivo experiments with human or porcine skin models have demonstrated that cubosome-encapsulated drugs, such as methotrexate or diclofenac, achieve significantly higher permeation rates compared to conventional creams or gels. For instance, cubosomes loaded with methotrexate exhibited a 2- to 3-fold increase in drug flux across the skin, ensuring higher concentrations in the dermal and subcutaneous layers where RA inflammation occurs. Moreover, the cubic phase structure of cubosomes allows for sustained drug release, reducing the need for frequent applications. This controlled release is particularly beneficial for RA patients, as it maintains therapeutic drug levels at the site of inflammation over extended periods. Advanced techniques, such as surface functionalization with polyethylene glycol (PEG) or hyaluronic acid, have further enhanced cubosome penetration by improving their hydrophilicity and interaction with skin tissues. These developments underscore the potential of cubosomes to overcome the skin barrier, making them a highly effective transdermal delivery system for RA¹².

9.3. Anti-Inflammatory and Therapeutic Efficacy:

Cubosome formulations have shown promising anti-inflammatory effects in preclinical RA models. For example, cubosomes loaded with diclofenac exhibited prolonged anti-inflammatory activity compared to traditional gels, reducing paw edema and cytokine levels in animal studies. Additionally, cubosomes carrying biologics, such as anti-TNF-α agents, have demonstrated enhanced therapeutic outcomes by maintaining drug stability and enabling localized delivery. In animal models of RA, such as collagen-induced arthritis in rats, cubosome-based formulations have shown remarkable anti-inflammatory effects. For example, cubosomes loaded with diclofenac reduced paw edema and pro-inflammatory cytokine levels (e.g., TNF-α, IL-6) more effectively than commercial gels, with effects lasting up to 24 hours after a single application. This prolonged activity is attributed to the sustained release properties of cubosomes, which maintain therapeutic drug concentrations at the site of inflammation. Similarly, cubosomes carrying methotrexate have demonstrated enhanced therapeutic outcomes by targeting synovial tissues, reducing joint swelling, and preventing cartilage degradation. Beyond small molecules, cubosomes have shown promise in delivering biologics, such as anti-TNF-α antibodies (e.g., infliximab), which are critical for managing severe RA. The cubic structure protects these sensitive molecules from enzymatic degradation in the skin, ensuring their bioactivity upon reaching the target site. In vivo studies have reported that cubosome-encapsulated biologics achieve localized delivery to inflamed joints, resulting in reduced systemic exposure and fewer side effects, such as immunosuppression or gastrointestinal toxicity. The therapeutic efficacy of cubosomes is further enhanced by their ability to co-deliver multiple drugs. For instance, combining an NSAID with a DMARD in a single cubosome formulation can address both acute inflammation and long-term disease progression, offering a synergistic therapeutic effect. These findings highlight the versatility of cubosomes in delivering diverse RA therapeutics with improved efficacy and safety profiles ¹³.

9.4. Multifunctional Cubosomes:

Innovations in cubosome design include multifunctional systems that combine drug delivery with diagnostic or imaging capabilities. For instance, cubosomes co-loaded with anti-inflammatory agents and imaging probes (e.g., fluorescent dyes) allow for real-time monitoring of drug distribution and therapeutic response. These advancements pave the way for personalized RA treatment strategies. Recent advancements in cubosome technology have led to the development of multifunctional systems that integrate drug delivery with diagnostic or imaging capabilities, paving the way for personalized RA treatment ¹⁴. Multifunctional cubosomes are designed to perform multiple roles, such as delivering therapeutics, monitoring drug distribution, and assessing treatment response in real time. One approach involves co-loading cubosomes with therapeutic agents and imaging probes, such as fluorescent dyes or magnetic nanoparticles. For example, cubosomes encapsulating both methotrexate and a near-infrared fluorescent dye have been used to track drug distribution in preclinical models. These studies demonstrated that cubosomes accumulate preferentially in inflamed joints, allowing for targeted therapy and non-invasive monitoring via fluorescence imaging. Similarly, cubosomes loaded with gadolinium-based contrast agents have been explored for magnetic resonance imaging (MRI), enabling visualization of drug delivery and joint inflammation. Another innovative application is the incorporation of stimuli-responsive elements into cubosomes. For instance, pH-sensitive or temperature-responsive cubosomes can release their drug payload in response to the acidic or inflamed environment of RA-affected joints, enhancing therapeutic precision. Additionally, cubosomes functionalized with targeting ligands, such as folate or anti-CD44 antibodies, can selectively bind to inflamed synovial tissues, further improving drug specificity. Multifunctional cubosomes also hold potential for theranostic applications, combining therapy and diagnostics in a single platform. By integrating anti-inflammatory drugs with biomarkers for RA progression (e.g., matrix metalloproteinases), these systems could enable early detection of disease flares and guide treatment adjustments. Such advancements represent a significant step toward personalized medicine for RA, offering tailored solutions that address individual patient needs ¹⁵.

10. CONCLUSION:

The integration of artificial intelligence (AI) in the development of transdermal cubosomes for the chronotherapeutic management of rheumatoid arthritis (RA) represents a transformative advancement in personalized medicine. By leveraging AI-driven approaches, researchers have optimized the formulation of cubosomes, enabling precise drug delivery that aligns with the circadian rhythms of RA symptoms. These nanostructured systems offer enhanced skin penetration, controlled release, and improved therapeutic efficacy, addressing the limitations of conventional treatments. The synergy of AI-guided design and chronotherapy ensures targeted delivery of anti-inflammatory agents, minimizing systemic side effects and improving patient outcomes. As this field progresses, further exploration of AI-driven nanotechnology and chronobiology promises to revolutionize RA management, paving the way for innovative, patient-centric therapeutic strategies. These nanostructured carriers offer enhanced skin penetration, sustained release, and targeted therapeutic effects, addressing the limitations of conventional treatments. The synergy of AI's predictive modeling and cubosomal technology has facilitated the design of personalized, time-dependent therapies, improving patient outcomes by aligning drug administration with peak inflammatory periods. Furthermore, this innovative strategy demonstrates significant potential for scalability and adaptability, paving the way for advanced, patient-centric solutions in RA management. Continued exploration of AI-guided nanomedicine promises to revolutionize chronotherapeutic interventions, offering hope for more effective and tolerable treatments for chronic inflammatory conditions like RA.

11. REFERENCE:

1 Huanbutta K, Burapapadh K, Kraisit P, Sriamornsak P, Ganokratanaa T, Sangnim T. Artificial intelligence-driven pharmaceutical industry: A paradigm shift in drug discovery, formulation development, manufacturing, quality control, and post-market surveillance. Eur J Pharm Sci. 2024; 203:106938.

2 Noorain S, Srivastava V, Parveen B, Parveen R. Artificial intelligence in drug formulation development: Applications and future prospects. Curr Drug Metab. 2023; 24(9): 622–34.

3 Sachan AK, Sachan NK, Kumar S. Role of artificial intelligence in quality by design for pharmaceuticals. Curr Pharm Biotechnol. 2023; 24(12): 1509–22.

4 Kim HJ, Lee SH, Park CH. Artificial intelligence in pharmaceutical sciences: Revolutionizing formulation design and quality control. J Pharm Investig. 2023; 53(4): 567–82.

5 Choi YJ, Kim SY. Machine learning approaches for quality by design in pharmaceutical formulation: A review. Asian J Pharm Sci. 2024; 19(2): 100912.

6 Patel M, Chavda H. Application of artificial intelligence in quality by design for pharmaceutical development. Indian J Pharm Sci. 2022;84(5):1123–35.

7 Nath S, Yata VK. Recent advances in the use of cubosomes as drug carriers with special emphasis on topical applications. J Lipids. 2024; 2024: 9781354.

8 Shen Q, Wang Y, Du Y. Applications and recent advances in transdermal drug delivery systems for the treatment of rheumatoid arthritis. Int J Pharm. 2023; 635:122698.

9 Li J, Wang X, Zhang Q. Artificial intelligence in pharmaceutical manufacturing: Enhancing quality by design. Chin J Chem Eng. 2023; 65:123–34.

10 Chen Y, Liu H. Integrating artificial intelligence with quality by design for advanced pharmaceutical formulation. Acta Pharm Sin B. 2023; 13(9): 3789–802.

11 Tanaka R, Sato K. Artificial intelligence in pharmaceutical formulation: A quality by design perspective. J Pharm Sci (Japan). 2023; 143(6): 521–34.

12 Kumar P, Jain V. Role of artificial intelligence in optimizing pharmaceutical formulations under QbD framework. Indian J Pharm Educ Res. 2022; 56(4): 987–96.

13 Jiang T, Xie Y, Sun C. The dexamethasone acetate cubosomes as a potential transdermal delivery system for treating skin inflammation. J Drug Deliv Sci Technol. 2023; 79:104123.

14 Nguyen TH, Tran VD. AI-driven quality by design in pharmaceutical formulation: Opportunities and challenges. J Asian Pharm Technol. 2024; 12(3): 89–102.

15 Abbas F, Salehian M, Hou P, Moores J, Goldie J, Tsioutsios A, et al. Accelerated medicines development using a Digital Formulator and a Self-Driving Tableting DataFactory. arXiv [Preprint]. 2025 Mar 20; Available from: arXiv:2503.17411.

Received on 12.08.2025 Revised on 22.10.2025

Accepted on 10.12.2025 Published on 02.07.2026

Available online from July 15, 2026

Asian J. Res. Pharm. Sci. 2026; 16(3):316-322.

DOI: 10.52711/2231-5659.2026.00047

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.